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Background: SMARCA4 mutations have recently been identified as driving lesions of the ovarian small cell
carcinoma of hypercalcemic type (SCCHT). Familial occurrence of this neoplasm was described previously.
Methods: We looked for germline SMARCA4 alterations in eight patients with the SCCHT. DNA was extracted from
probands’ and their relatives’ blood. The SMARCA4 coding sequence, previously found altered in all the tumors, was
PCR amplified and sequenced in the germline DNA.
Results: Two patients carried a heterozygous germline SMARCA4 alteration: c.3760G > T and c.2352insG, respectively.
The analysis of the probands’ next of kins revealed that the c.3760G > T mutation was inherited by the proband and
her sister from their father, and the sisters’ four children also carried the mutation. The proband’s sister was diagnosed
with a carcinoma of the parotid gland at age 2. A brother of the other proband was tested negative.
Conclusions: Our study suggests that some women develop the ovarian SCCHT due to the inherited or possibly de
novo-occurring germline alterations in the SMARCA4 gene, however, its penetrance appears limited. Nevertheless,
because of high aggressiveness of the SCCHT, a molecular diagnostics of the SMARCA4 gene and careful follow-up
should be offered to patients with this cancer and their families.
Keywords: Small-cell carcinoma of hypercalcemic type, Immature teratoma, Parotid gland carcinoma, SMARCA4
mutation, Germline mutation, Ovarian cancerBackground
A small cell carcinoma of the ovary of hypercalcemic
type (SCCHT) is a rare and highly malignant neoplasm
affecting young females. In the largest published group
of patients the age of onset ranged from 9 to 43 years
(median 24 years). Microscopically, the predominant
population is that of small undifferentiated ovoid cells.
There are also foci of large cells with eosinophilic cyto-
plasm, with or without eccentrically displaced nuclei (rhab-
doid features). The architecture is heterogeneous and
disordered, with pseudofollicles [1,2].
The SCCHT grows rapidly and shows poor response
to available chemotherapies. Overall survival of affected* Correspondence: jkupry@coi.waw.pl
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article, unless otherwise stated.patients is generally short; it largely depends on a clinical
stage and ranges from 5 months to several years at the
FIGO I stage, and 2–23 months at the FIGO III stage [3].
Familial occurrence of the SCCHT has been described
in a few reports, and it led to death of young first degree
relatives [4-7]. Thus, identification of patients at risk of de-
velopment of this neoplasm and its early detection might
improve the prognosis.
Until recently, the SCCHT remained a mystery in terms
of histogenesis and molecular background [2,8-10]. In year
2013, our research group has described its development
in association with an ovarian immature teratoma and
brought to light its similarity to atypical teratoid/rhabdoid
tumor of the central nervous system (AT/RT). Based on
these findings and the fact that some AT/RTs may develop
due to SMARCA4 gene mutations [11], we performed an
analysis of this gene and identified SMARCA4-inactivating
mutations in two SCCHT analyzed [12]. Subsequently,d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Small cell carcinoma of hypercalcemic type (proband 2,
tumor 392). Histological pattern (HE staining, 200x).
Table 1 The PCR and sequencing primers for the exons in
which mutations were detected
Exon Forward primer Reverse primer
16* AGGACCCTCTGGTGTCCGAC TGTTGCTGGCAGCGGGTAC
26b CTCAACGTGGACCAGAAGGT TCAGCCCACACTCCCTTTAC
*Primers based on published sequences [16].
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neoplasm [13-15] and all these findings suggest that the
SCCHT is an ovarian rhabdoid tumor.
The SMARCA4 gene encodes an ATP-dependent heli-
case BRG1 which belongs to the SWI/SNF (mating type
SWItching defective/Sucrose Non Fermenting) complex
and is involved in epigenetic regulation of gene expres-
sion via chromatin remodeling. The importance of dif-
ferent SMARCA4 alterations, their penetrance and traits
of inheritance are just beginning to be explored. In this
study we present germline alterations of the SMARCA4
gene in two patients diagnosed with the SCCHT; one of




Initially, we identified eight SCCHT with SMARCA4
mutations; normal tissue from all the patients was avail-
able. Two of the eight patients had germline SMARCA4
alterations and they are subjects of this study (the ana-
lysis of somatic molecular changes in the larger group
including the eight tumors is a matter of a separate
study, Dansonka-Mieszkowska et al. unpublished). In the
next step, normal tissue used for DNA extraction was
obtained from the relatives of both probands. All adult
subjects gave written informed consent and the study
was approved by the local ethics committee (ref. no 13/
2008).
Proband 1 (PJK1182)
A 35 y.o. patient underwent cesarean section in the 33rd
week of pregnancy during which the SCCHT of the right
ovary was removed. Within this tumor there was a focus
of immature teratoma [12]. Subsequent staging laparot-
omy revealed International Federation of Gynecologists
and Obstetricians (FIGO) stage IIIB neoplasm. The pa-
tient received 3 lines of combination chemotherapy and
died 12 months after the initial diagnosis due to progres-
sion of the disease.
Proband 2 (tumor 392)
A 21 y.o. patient was admitted to the hospital because of
a tumor of the left ovary, ascites and right-sided hydro-
thorax. She underwent radical gynecological surgery and
was diagnosed with FIGO IV ovarian SCCHT (Figure 1).
The patient received 6 courses of paclitaxel and carbo-
platin and died 6 months later due to progression of the
disease.
Analysis of SMARCA4 gene mutations
Genomic DNA was isolated from formalin-fixed paraffin-
embedded or frozen tissues using the QIAamp DNA
Extraction Kit (Qiagen, Hilden, Germany), according tothe manufacturer’s instructions. The SMARCA4 coding
sequence [GenBank: NG_011556.1], previously found al-
tered in the tumors, was PCR amplified and sequenced in
the germline DNA. The PCR and sequencing primer se-
quences of exon 16 (Table 1) were taken from the publica-
tion by Medina et al. [16]; primer sequences for exon 26b
(Table 1) were designed personally using the Primer3 algo-
rithm. The PCR mixture was prepared according to the
protocol provided with AmpliTaq Gold PCR kit (Life
Technologies, Foster City, USA). Thermal cycling condi-
tions for both exons were as follows: an initial denatur-
ation at 95°C for 5 min; followed by 36 cycles of sample
denaturation at 94°C for 30 s, primers annealing at 59°C
for 30 s, and product extension at 72°C for 30 s, followed
by a final 7 min extension at 72°C. All DNA samples were
sequenced in the ABI PRISM 3100 sequencer with the use
of BigDye Terminator Cycle Sequencing Kit (v.3.1) (both
from Life Technologies), according to the manufacturer’s
recommendations.
Results
Mutations in the SMARCA4 gene and the family history of
cancer
Proband 1
A SMARCA4 nonsense mutation c.3760G > T with the
loss of heterozygosity was found in the ovarian SCCHT
from this patient. This alteration led to premature ter-
mination of the BRG1 protein, p.(Glu1254*) (see Table 2).
Analysis of germline DNA from the proband revealed






Tumor DNA Germline DNA
Proband 1 35 IIIB Negative Exon 26 c.3760G > T; p.(Glu1254*) (homozygous) Heterozygous
Proband 2 21 IV Negative Exon 16 c.2352insG; p.(Lys785Glufs*39) (homozygous) Heterozygous
aSMARCA4 expression evaluated with Brg-1 clone G-7antibody [12]. *means a stop codon.
Figure 2 Chromatograms of germline SMARCA4 mutations. (A) c.3760G > T in proband 1. (B) c.2352insG in proband 2.
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quent analysis of her family has shown the same muta-
tion in the germline of her six first- and second-degree
relatives (Figure 3).
The only sibling (sister) of the proband was diagnosed
with carcinoma of the parotid gland at age 2. The carcin-
oma was described as solid basal, partially cylindromatous
with extensive cord-like infiltration and hyalinisation, dif-
ficult to interpret, presumably adenoid cystic carcinoma
(the tumor had been evaluated by several expert pathol-
ogists, slides and blocks no longer available). After sur-
gery she received radiotherapy (4600 R/g) and has been
remaining free of cancer for 35 years now. No other neo-
plasms in the first and second-degree relatives of the pro-
band were reported (the father and his two sisters and one
brother).
Proband 2
Another SMARCA4 homozygous mutation – insertion of
a single guanine nucleotide c.2352insG (Figure 2B), was
found in the other tumor investigated. This frameshift al-
teration resulted in a premature termination of the BRG1
protein p.(Lys785Glufs*39) (Table 2). The same mutation,
yet heterozygous, was identified in the proband’s blood.
Among the proband’s family members (parents, two
brothers), only one brother agreed for examination of hisFigure 3 A pedigree of the proband’s 1 family. The proband
(P, II:1) with SCCHT had a germline mutation in SMARCA4 exon 26
(c.3760G > T) inherited from her father (I:1). This mutation was also
identified in the proband’s two sons (III:1, III:2), sister (II:3) and in the
sister’s two children (III:3, III:4). (+/−) heterozygous mutation carrier in
the germline; (+/+) wild-type in the germline. A diagonal line
through a symbol indicates that the person is deceased.germline DNA and was tested negative (Figure 4). Accord-
ing to the information obtained from this brother, there
was no history of cancer in their parents and the parents’
siblings (altogether 6).
Discussion
SMARCA4 gene alterations have recently been found to
underlie a development of the ovarian small cell carcin-
oma of hypercalcemic type [12-15]. In this study we
present two patients with novel germline SMARCA4 al-
terations. The pedigree chart of one family shows that
the c.3760G > T; p.(Glu1254*) SMARCA4 mutation, oc-
curring across three generations, was inherited in an
autosomal manner.
This is only the fifth family with the ovarian SCCHT
and the SMARCA4 germline mutation, after four pedi-
grees published by Witkowski et al. [15]. In each family
of the latter study, the mutation of SMARCA4 gene was
carried by a mother and a daughter, and all of them were
affected by an ovarian cancer, mostly the SCCHT. In
one of those families, similarly to our results, the muta-
tion was also identified in the proband’s father. Interest-
ingly, in both our and the Witkowski’s et al. [15] study,
all examined offsprings carried the germline SMARCA4
mutation detected in their ancestors. Since not all muta-
tion carriers have been diagnosed with cancer, the pene-
trance of the SMARCA4 gene appears incomplete. This
has also been raised by Hasselblatt et al. [17] on theFigure 4 A pedigree of the proband’s 2 family. The proband
(P, II:1) with SCCHT had a germline mutation in SMARCA4 exon 16
(c.2352insG), while her brother (II:2) turned out to be unaffected. The
proband’s parents (I:1, I:2) and her second brother (II:3) refused to
attend the study. (+/−) heterozygous mutation carrier in the
germline; (+/+) wild-type in the germline. A diagonal line through a
symbol indicates that the person is deceased.
Moes-Sosnowska et al. Orphanet Journal of Rare Diseases  (2015) 10:32 Page 5 of 6basis of data on children with AT/RT carrying a germline
SMARCA4 mutation, and their families.
Recently, other groups have also found germline SMARCA4
mutations in patients with the SCCHT [13,14], however,
they did not present a pedigree analysis. In accordance
with our results, all SMARCA4 germline mutations de-
scribed to date caused a premature stop codon or altered
splice site, and were associated with somatic loss of the
wild-type allele and SMARCA4/BRG1 protein expression
in the tumors [11,13-15,18,19].
In mammalian cells, the SWI/SNF complex exhibits
the tumor suppressor activity, and SMARCA4/BRG1
protein is one of its two most essential subunits. Mal-
function of the complex may negatively affect cell migra-
tion, nuclear hormone receptors signaling, embryonic
stem cell programs, lineage-specific differentiation and
cell proliferation [20]. The both germline alterations in
the SMARCA4 gene reported by our research team oc-
curred in the important ATPase domain (functioning as
the motor units that convert ATP energy to mechanical
movement) [21].
Mutations in the SMARCA4 gene appear to be associ-
ated with various cancers including malignant melanoma,
non-small cell lung cancer, head and neck and pancreatic
cancer [22]. Families with germline SMARCA4 mutations
have been reported to develop malignant rhabdoid tumors
(SCCHT, AT/RT, renal rhabdoid tumor) and yolk sac
tumor (YST), all belonging to the group of embryonal tu-
mors [15,17,18]. Our study apparently adds two tumor
types to the spectrum of cancers observed in carriers of
SMARCA4 mutations, i.e., the ovarian immature teratoma
and carcinoma of the parotid gland. The immature tera-
toma showed diminished expression of the BRG1 pro-
tein compared with normal tissues, thus it presumably
retained one wt SMARCA4 allele [12]. As to the parotid
gland carcinoma, we do not know whether there was
LOH at the gene locus in this tumor. However, other au-
thors describing SMARCA4 mutations in different cancers
did not evaluate LOH as well (Shain & Pollack [22]).
Haploinsufficiency of the SMARCA4 gene should also
be taken into account as a potential mechanism of tumor
progression, since it was previously reported by Bultman
et al. for heterozygous Smarca4 (+/−) mice developing
mammary tumors [23].
Previously, we demonstrated foci of immature teratoma
(a germ cell tumor) in two ovarian SCCHT (including the
first one presented in this study) [12]. Thus, some SCCHT
appear to originate from immature teratoma, as many
other secondary tumors developing in this pluripotential
neoplasm, and this does not contradict their assignment
to the group of rhabdoid tumors. In one of their recent
studies, Witkowski et al. [19] found a germline SMARCA4
mutation in a patient with an original diagnosis of ovarian
immature teratoma and suggested that it might have beena malignant rhabdoid tumor. As we have demonstrated,
rhabdoid tumors may develop in association with the im-
mature teratoma and this neoplasm may be observed in
the SMARCA4 mutation carriers.
The penetrance of the SMARCA4 gene appears to be
limited, and factors that modify it are to be discovered.
Based on pedigrees described by Witkowski et al. [15]
and our study, it appears that female carriers are more
susceptible to cancers than males. Due to high aggres-
siveness of the SCCHT, it seems reasonable to offer the
patients with this cancer and their families a molecular
diagnostics of the SMARCA4 gene. SMARCA4 mutation
carriers should be subjected to thorough observation, in-
cluding ultrasonographic and magnetic resonance im-
aging of potentially affected organs. Since the SCCHT
develops to age 44, an option might be a prophylactic
oophorectomy in older patients who completed their
families, provided that they would be informed that the
risk of the disease has not yet been determined. It ap-
pears that women from families with more than one fe-
male members affected by the SCCHT are at particular
risk of developing this neoplasm.
Conclusions
In conclusion, our study suggests that some women de-
velop the ovarian SCCHT due to the inherited or possibly
de novo-occurring germline alteration in one SMARCA4
gene allele, with subsequent loss of the wild type allele.
More families with SMARCA4 mutations have to be de-
scribed to precisely assess the risk of the SCCHT and
other neoplasms, and to establish adequate medical care
of the mutations carriers.
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